Exploring the Expression and Prognosis of Mismatch Repair Proteins and PD-L1 in Colorectal Cancer in a Chinese Cohort

References

• Kishore C, Bhadra P. Current advancements and future perspectives of immunotherapy in colorectal cancer research. Eur J Pharmacol. 2021;893:173819. doi:10.1016/j.ejphar.2020.173819
   PubMed Web of Science ®Google Scholar
• Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361–375. doi:10.1038/s41575-019-0126-x
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413. doi:10.1126/science.aan6733
   PubMed Web of Science ®Google Scholar
• Germani M, Moretto R. Immune checkpoint inhibitors in mismatch repair proficient/microsatellite stable metastatic colorectal cancer patients: insights from the AtezoTRIBE and MAYA trials. Cancers. 2021;14(1):52. doi:10.3390/cancers14010052
   PubMed Web of Science ®Google Scholar
• Schrock AB, Ouyang C, Sandhu J, et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 2019;30(7):1096–1103. doi:10.1093/annonc/mdz134
   PubMed Web of Science ®Google Scholar
• Boland CR, Thibodeau SN, Hamilton SR, et al. A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58(22):5248–5257.
   PubMed Web of Science ®Google Scholar
• Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 2008;135(4):1079–1099. doi:10.1053/j.gastro.2008.07.076
   PubMed Web of Science ®Google Scholar
• Alwers E, Jansen L, Bläker H, et al. Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study. Mol Oncol. 2020;14(2):363–372. doi:10.1002/1878-0261.12611
   PubMed Web of Science ®Google Scholar
• Koenig JL, Toesca DAS, Harris JP, et al. Microsatellite instability and adjuvant chemotherapy in stage II colon cancer. Am J Clin Oncol. 2019;42(7):573–580. doi:10.1097/COC.0000000000000554
   PubMed Web of Science ®Google Scholar
• Taieb J, Shi Q, Pederson L, et al. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. Ann Oncol. 2019;30(9):1466–1471. doi:10.1093/annonc/mdz208
   PubMed Web of Science ®Google Scholar
• Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349(3):247–257. doi:10.1056/NEJMoa022289
   PubMed Web of Science ®Google Scholar
• Wainberg Z, Fuchs C, Tabernero J, et al. Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1–positive (CPS ≥10) advanced G/GEJ cancer in the Phase II KEYNOTE-059 (cohort 1) and Phase III KEYNOTE-061 and KEYNOTE-062 studies. J Clin Oncol. 2020;38(4_suppl):427. doi:10.1200/JCO.2020.38.4_suppl.427
   Web of Science ®Google Scholar
• De Marchi P, Leal LF, Duval Da Silva V, et al. PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC). J Clin Pathol. 2021;74(11):735–740. doi:10.1136/jclinpath-2020-206832
   PubMed Web of Science ®Google Scholar
• Carter JM, Polley MC, Leon-Ferre RA, et al. Characteristics and spatially defined immune (micro)landscapes of Early-stage PD-L1-positive triple-negative breast cancer. Clin Cancer Res. 2021;27(20):5628. doi:10.1158/1078-0432.CCR-21-0343
   PubMed Web of Science ®Google Scholar
• Yamashita K, Iwatsuki M, Harada K, et al. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer. Gast Cancer. 2020;23(1):95–104. doi:10.1007/s10120-019-00999-9
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Le DT, Kim TW, Van Cutsem E, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer KEYNOTE-164. J Clin Oncol. 2020;38(1):11–19. doi:10.1200/JCO.19.02107
   PubMed Web of Science ®Google Scholar
• Salem ME, Bodor JN, Puccini A, et al. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors. Int J Cancer. 2020;147(10):2948–2956. doi:10.1002/ijc.33115
   PubMed Web of Science ®Google Scholar
• Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-The stable evidence. Nat Rev Clin Oncol. 2010;7(3):153–162. doi:10.1038/nrclinonc.2009.237
   PubMed Web of Science ®Google Scholar
• Guo TA, Wu YC, Tan C, et al. Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: a single-center retrospective study of 1834 Chinese patients with Stage I-IV colorectal cancer. Int J Cancer. 2019;145(6):1625–1634. doi:10.1002/ijc.32489
   PubMed Web of Science ®Google Scholar
• Wen F, Jing R, Yu W, et al. Correlation between the expression of four mismatch repair proteins and clinicopathological features of colorectal cancer in elderly patients. Chin J Geriatr. 2018;1:54–56.
   Google Scholar
• Xiao H, Can X, Ye K, et al. Correlation between mismatch-repair protein expression and clinicopathologic features in 658 colorectal cancers. Chin J Pathol. 2018;11:827–833.
   Google Scholar
• Yang H, Yu Z, Xiang S, et al. Analysis of mismatch repair protein expression and clinicopathological characteristics in radical resection specimens of colorectal cancer based on random forest algorithm. Chin J Cancer Prev Treat. 2022;29(06):408–413.
   Google Scholar
• Ping H, Li L, Qiu W, et al. Detection of mismatch repair protein MLH1 and PMS2 expression in colorectal cancer tissues by optimized automatic immunohistochemical staining scheme. J Mod Oncol. 2021;29(13):2254–2257.
   Google Scholar
• Huil YS, Xiang L. Expression of MLH1, MSH2, MSH6 and PMS2 proteins in colorectal cancer and their significance in the screening of Lynch syndrome. Chin J Clin Exp Pathol. 2017;33(04):360–364.
   Google Scholar
• Morgan S, Slodkowska E, Parra-Herran C, et al. PD -L1, RB 1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type, of the uterine cervix. Histopathology. 2019;74(7):997–1004. doi:10.1111/his.13825
   PubMed Web of Science ®Google Scholar
• Berntsson J, Eberhard J, Nodin B, et al. Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: relationship with sidedness and prognosis. Oncoimmunology. 2018;7(8):e1465165. doi:10.1080/2162402X.2018.1465165
   PubMed Web of Science ®Google Scholar
• Kir G, Olgun ZC, Soylemez T, et al. PD-L1 expression in mismatch repair-deficient endometrial carcinoma and tumor-associated immune cells: differences between MLH1 methylated and nonmethylated subgroups. Int J Gynecol Pathol. 2021;40(6):575–586. doi:10.1097/PGP.0000000000000750
   PubMed Web of Science ®Google Scholar
• Gelsomino F, Barbolini M, Spallanzani A, et al. The evolving role of microsatellite instability in colorectal cancer: a review. Cancer Treat Rev. 2016;51:19–26. doi:10.1016/j.ctrv.2016.10.005
   PubMed Web of Science ®Google Scholar
• Xue H, Bin Z, Jun D, et al. Relevance between mismatch repair protein expression status and clinicopathological features of patients with stage II colorectal cancer and its impact on prognosis. Chin Med. 2021;16(05):725–728.
   Google Scholar
• Chen L, Chen G, Zheng X, et al. Expression status of four mismatch repair proteins in patients with colorectal cancer: clinical significance in 1238 cases. Int J Clin Exp Pathol. 2019;12(10):3685–3699.
   PubMed Web of Science ®Google Scholar
• Jung KW, Won YJ, Hong S, et al. Prediction of cancer incidence and mortality in Korea, 2021. Cancer Res Treat. 2021;53(2):316–322. doi:10.4143/crt.2021.290
   PubMed Web of Science ®Google Scholar
• Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669–685. doi:10.1001/jama.2021.0106
   PubMed Web of Science ®Google Scholar
• Kahi CJ, Boland CR, Dominitz JA, et al. Colonoscopy surveillance after colorectal cancer resection: recommendations of the US multi-society task force on colorectal cancer. Am J Gastroenterol. 2016;111(3):337–46; quiz 47. doi:10.1038/ajg.2016.22
   PubMed Web of Science ®Google Scholar
• Sharma R, Abbasi-Kangevari M, Abd-Rabu R, et al. Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet Gastroenterol Hepatol. 2022;7(7):627–647. doi:10.1016/S2468-1253(22)00044-9
   PubMed Web of Science ®Google Scholar
• Hao C, Jun Q, Yu H. Research progress on the FOLFOXIRI regimen as first-line therapy for advanced colorectal cancer. Chin Clin Oncol. 2021;48(11):587–592.
   Google Scholar
• Hong M, Qi Z, Xian Z. Advances in research on maintenance therapy of metastatic colorectal cancer. J Mod Oncol. 2021;29(02):361–364.
   Google Scholar
• Akdeniz N, Kaplan MA, Uncu D, et al. The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study. Int J Colorectal Dis. 2021;36(6):1311–1319. doi:10.1007/s00384-021-03888-9
   PubMed Web of Science ®Google Scholar
• Benson AB, Venook AP, Cederquist L, et al. Colon Cancer, Version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(3):370–398. doi:10.6004/jnccn.2017.0036
   PubMed Web of Science ®Google Scholar
• Liu DX, Li DD, He W, et al. PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer. Oncoimmunology. 2020;9(1):1711650. doi:10.1080/2162402X.2020.1711650
   PubMed Web of Science ®Google Scholar
• Hu H, Kang L, Zhang J, et al. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, Phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(1):38–48. doi:10.1016/S2468-1253(21)00348-4
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Vermeulen L, Guinney J, et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017;17(2):79–92. doi:10.1038/nrc.2016.126
   PubMed Web of Science ®Google Scholar
• Jiang X, Wang J, Deng X, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18(1):10. doi:10.1186/s12943-018-0928-4
   PubMed Web of Science ®Google Scholar
• Lecocq Q, Keyaerts M, Devoogdt N, et al. The next-generation immune checkpoint LAG-3 and its therapeutic potential in oncology: third time’s a charm. Int J Mol Sci. 2020;22(1):75. doi:10.3390/ijms22010075
   PubMed Web of Science ®Google Scholar
• Gaikwad S, Agrawal MY, Kaushik I, et al. Immune checkpoint proteins: signaling mechanisms and molecular interactions in cancer immunotherapy. Semin Cancer Biol. 2022;86(Pt 3):137–150. doi:10.1016/j.semcancer.2022.03.014
   PubMedGoogle Scholar
• Lizardo DY, Kuang C, Hao S, et al. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: from bench to bedside. Biochim Biophys Acta Rev Cancer. 2020;1874(2):188447. doi:10.1016/j.bbcan.2020.188447
   PubMed Web of Science ®Google Scholar
• Paterson AM, Brown KE, Keir ME, et al. The programmed death-1 ligand 1: B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol. 2011;187(3):1097–1105. doi:10.4049/jimmunol.1003496
   PubMed Web of Science ®Google Scholar
• Li Y, Liang L, Dai W, et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Mol Cancer. 2016;15(1):55. doi:10.1186/s12943-016-0539-x
   PubMed Web of Science ®Google Scholar
• Gao Q, Wang XY, Qiu SJ, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009;15(3):971–979. doi:10.1158/1078-0432.CCR-08-1608
   PubMed Web of Science ®Google Scholar
• Hu K, Wang ZM, N LJ, et al. CLEC1B expression and PD-L1 expression predict clinical outcome in hepatocellular carcinoma with tumor hemorrhage. Transl Oncol. 2018;11(2):552–558. doi:10.1016/j.tranon.2018.02.010
   PubMed Web of Science ®Google Scholar
• Wang S, Yuan B, Wang Y, et al. Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a meta-analysis. Int J Colorectal Dis. 2021;36(1):117–130. doi:10.1007/s00384-020-03734-4
   PubMed Web of Science ®Google Scholar
• Zhao T, Li Y, Zhang J, et al. PD-L1 expression increased by IFN-γ via JAK2-STAT1 signaling and predicts a poor survival in colorectal cancer. Oncol Lett. 2020;20(2):1127–34.7. doi:10.3892/ol.2020.11647
   PubMed Web of Science ®Google Scholar
• Tang M, Zheng Z, Shang J, et al. Risk analysis of positive PD-L1 expression and clinicopathological features and survival prognosis in patients with colorectal cancer: systematic review and meta-analysis. J Healthc Eng. 2022;2022:8212486. doi:10.1155/2022/8212486
   PubMed Web of Science ®Google Scholar
• Hsieh RC, Krishnan S, Wu RC, et al. ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. Sci Immunol. 2022;7(72):eabl9330. doi:10.1126/sciimmunol.abl9330
   PubMed Web of Science ®Google Scholar
• Thibaudin M, Limagne E, Hampe L, et al. Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer. Cancer Immunol Immunother. 2022;71(10):2549–2563. doi:10.1007/s00262-022-03182-9
   PubMed Web of Science ®Google Scholar